drugset
Drugs / GLA-AF
last change Jan 2025 re-read 2 minutes ago

GLA-AF

also known as Gluco-pyranosylphospho-lipid A aqueous formulation · glucopyranosyl lipid adjuvant - aqueous formulation · Glucopyranosyl-Lipid A

Other / unclassified

Investigated by
Baylor College of Medicine · George Washington University · National Institute of Allergy and Infectious Diseases (NIAID) · Access to Advanced Health Institute (AAHI) · Centro de Pesquisas René Rachou · Children's National Research Institute
+4 more · Defense Advanced Research Projects Agency · Johns Hopkins University · Medicago · University of California, San Francisco

Trials 7 · a red edge is where a trial was stopped

today NCT03110757 · Ph 1 NCT03172975 · Ph 2 NCT02476773 · Ph 1 NCT02337855 · Ph 1 NCT01717950 · Ph 1 NCT01657929 · Ph 1 NCT01385189 · Ph 1
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT03110757 May 2018 → Nov 2019 intestinal schistosomiasis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT02476773 Jan 2016 → Jun 2017 hookworm infectious disease Baylor College of Medicine Completed No outcome recorded
Phase 1 NCT02337855 Feb 2015 → Jan 2017 intestinal schistosomiasis National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01717950 Sep 2013 → Jun 2015 hookworm infectious disease Baylor College of Medicine Completed No outcome recorded
Phase 1 NCT01657929 Sep 2012 → Jan 2014 avian influenza Access to Advanced Health Institute (AAHI) Completed No outcome recorded
Phase 1 NCT01385189 May 2012 → Jan 2015 hookworm infectious disease Baylor College of Medicine Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03172975 Mar 2018 → Dec 2024 hookworm infectious disease Baylor College of Medicine Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01966900 Comparator Oct 2013 → Nov 2015 HIV infectious disease Imperial College London Completed No outcome recorded
Phase 1 NCT01922284 Background Jun 2013 → Jan 2014 HIV infectious disease Imperial College London Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as GLA-AF “GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity.” NCT01717950 ↗
8

NCT01657929 ↗

NCT03172975 ↗

NCT01966900 ↗

NCT02337855 ↗

NCT01385189 ↗

NCT03110757 ↗

NCT01922284 ↗

NCT02476773 ↗
Known as Gluco-pyranosylphospho-lipid A aqueous formulation “Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist” NCT03110757 ↗
Known as glucopyranosyl lipid adjuvant - aqueous formulation “the adjuvant is glucopyranosyl lipid adjuvant - aqueous formulation (GLA-AF).” NCT01966900 ↗
Known as Glucopyranosyl-Lipid A “an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)” NCT03172975 ↗
Action Activate “GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity.” NCT01717950 ↗
Modality Other / unclassified “5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant” NCT01922284 ↗
Route Intramuscular “Vaccinations were administered via intramuscular injection on days 0, 56, and 112.” PMID 28464026 ↗ May 2017